In particular, venetoclax has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) with a 17p-deletion or TP53 mutation15. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.